"Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016" is now available at Fast Market Research

A prolonged period of subdued oil prices may see Saudi Arabia cut back on high value drug spending. While public spending on healthcare will remain high as a result of the sensitive nature of the sector and its political importance, governments will enforce cost-containment measures, including price cuts on medicines and private sector engagement, to limit healthcare spending.

Headline Expenditure Projections

Pharmaceuticals: SAR28.4bn (USD7.6bn) in 2014 to SAR31.8bn (USD8.5bn) in 2015; +11.9% in both local currency and US dollar terms. Forecast unchanged from Q 4 15.
Healthcare: SAR103.7bn (USD27.7bn) in 2014 to SAR119.8bn (USD31.9bn) in 2015; +15.5% in both local currency and US dollar terms. Forecast in line with Q 4 15.

Risk/Reward Index

The Saudi Arabia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

Full Report Details at
- http://www.fastmr.com/prod/1082801_saudi_arabia_pharmaceuticals.aspx?afid=301

BMI's Saudi Arabia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Saudi Arabia pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Saudi Arabia, to test other views - a key input for successful budgeting and strategic business planning in the Saudi pharmaceutical and healthcare market.
* Target business opportunities and risks in the Saudi pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Saudi Arabia.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

* Healthcare:

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Ukraine Pharmaceuticals & Healthcare Report Q1 2016
- Thailand Pharmaceuticals & Healthcare Report Q1 2016
- Oman Pharmaceuticals & Healthcare Report Q1 2016
- Peru Pharmaceuticals & Healthcare Report Q1 2016